Molly Cathleen Hutchins, PA
Physician Assistant · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Molly Cathleen Hutchins’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$3,826
Medicare paid this office $3,826 for 27 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Mastectomy | 19 | More than 77% of doctors who do this |
| Melanoma (skin cancer) excision | 11 | More than 64% of doctors who do this |
Who their Medicare patients are
27 Original Medicare patients in 2024. Average age 74 · Health risk score 1.13. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: Cancer 75% · High blood pressure 56%.
The office billed $274,403, Medicare allowed $4,792 and paid $3,826; for 62 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 27 | 62 | 74 | 1.13 | $274,403 | $3,826 |
| 2021 | 78 | 156 | 68 | 1.62 | $37,165 | $5,011 |
| 2020 | 67 | 156 | 66 | 1.49 | $26,134 | $3,398 |
| 2019 | 73 | 146 | 68 | 1.38 | $29,937 | $4,333 |
| 2018 | 76 | 180 | 66 | 1.50 | $37,654 | $5,507 |
| 2017 | 87 | 195 | 68 | 1.67 | $41,306 | $7,839 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2021: 3 services
| Return visit (30+ min) | 28 | $1,443 | $44 |
| Short return visit (20+ min) | 32 | $903 | $24 |
| Insertion of needle into vein for collection of blood sample | 17 | $51 | $3 |
2020: 3 services
| Return visit (30+ min) | 26 | $768 | $26 |
| Short return visit (20+ min) | 29 | $549 | $16 |
| Insertion of needle into vein for collection of blood sample | 18 | $75 | $3 |
2019: 3 services
| Return visit (30+ min) | 32 | $1,558 | $40 |
| Short return visit (20+ min) | 26 | $782 | $23 |
| Insertion of needle into vein for collection of blood sample | 24 | $77 | $3 |
2018: 3 services
| Return visit (30+ min) | 41 | $2,355 | $43 |
| Short return visit (20+ min) | 34 | $1,235 | $32 |
| Insertion of needle into vein for collection of blood sample | 23 | $88 | $3 |
2017: 3 services
| Short return visit (20+ min) | 46 | $2,224 | $39 |
| Return visit (30+ min) | 33 | $1,983 | $50 |
| Insertion of needle into vein for collection of blood sample | 23 | $76 | $3 |
Medicaid work
$1,151 in 2022
Medicaid paid $1,151 for 27 billed services this clinician did in 2022, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 27 | $1,151 |
| 2022 | 27 | 1 | 22 | $1,151 |
| 2021 | 311 | 4 | 30 | $18,737 |
| 2020 | 269 | 3 | 24 | $18,084 |
| 2019 | 386 | 3 | 30 | $26,009 |
| 2018 | 377 | 3 | 35 | $25,856 |
See the largest Medicaid services in earlier years
2021
| Short return visit (20+ min) | 222 | $13,321 |
| Return visit (30+ min) | 63 | $4,468 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13 | $720 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 13 | $229 |
2020
| Short return visit (20+ min) | 175 | $10,726 |
| Return visit (30+ min) | 82 | $7,135 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 12 | $223 |
2019
| Return visit (30+ min) | 210 | $16,160 |
| Short return visit (20+ min) | 162 | $9,578 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 14 | $271 |
2018
| Short return visit (20+ min) | 216 | $13,424 |
| Return visit (30+ min) | 147 | $12,403 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 14 | $30 |
Drugs they prescribed that Part D paid
$264
Pharmacies billed $264 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 63% of their Part D prescriptions (27 of 43) in 2024. Too few prescriptions to compare fairly with other clinicians.
43 generic and 0 brand-name prescriptions · $264 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tramadol | 25 | $39 | $2 |
Year by year
| 2024 | 43 | 29 | 63% (27) | 0% | $264 |
| 2022 | 198 | 81 | None | None | $28,819 |
| 2021 | 1,001 | 281 | 1% (13) | 12% | $91,555 |
| 2020 | 1,272 | 304 | 2% (23) | 15% | $72,951 |
| 2019 | 699 | 229 | 3% (23) | None | $48,329 |
| 2018 | 681 | 207 | 6% (38) | None | $45,801 |
| 2017 | 474 | 142 | 8% (40) | None | $22,312 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 4 drugs
| Eliquis | 15 | $14,294 | $953 |
| Lisinopril | 16 | $158 | $10 |
| Atorvastatin | 14 | $138 | $10 |
| Rosuvastatin | 11 | $136 | $12 |
2021: 22 drugs
| Albuterol Sulfate Hfa | 27 | $1,122 | $42 |
| Valproic Acid | 12 | $947 | $79 |
| Gabapentin | 30 | $777 | $26 |
| Atorvastatin | 46 | $701 | $15 |
| Losartan | 39 | $487 | $12 |
| Levothyroxine | 20 | $456 | $23 |
| Lisinopril | 61 | $399 | $7 |
| Diclofenac | 15 | $294 | $20 |
| Metformin Hcl Er | 20 | $284 | $14 |
| Omeprazole | 22 | $250 | $11 |
| Pantoprazole | 11 | $224 | $20 |
| Valproic Acid | 12 | $214 | $18 |
| Metformin | 28 | $195 | $7 |
| Amlodipine Besylate | 40 | $185 | $5 |
| Hydrochlorothiazide | 18 | $124 | $7 |
| Glipizide | 13 | $106 | $8 |
| Trazodone | 21 | $93 | $4 |
| Sertraline | 11 | $87 | $8 |
| Glimepiride | 11 | $78 | $7 |
| Naproxen | 12 | $74 | $6 |
| Cephalexin | 12 | $50 | $4 |
| Atenolol | 13 | $43 | $3 |
2020: 32 drugs
| Albuterol Sulfate Hfa | 57 | $3,046 | $53 |
| Gabapentin | 52 | $1,548 | $30 |
| Ventolin Hfa | 12 | $922 | $77 |
| Atorvastatin | 55 | $769 | $14 |
| Losartan | 43 | $574 | $13 |
| Levothyroxine | 22 | $518 | $24 |
| Lisinopril | 56 | $494 | $9 |
| Omeprazole | 43 | $484 | $11 |
| Atenolol | 23 | $403 | $18 |
| Metformin Hcl Er | 24 | $388 | $16 |
| Pantoprazole | 15 | $328 | $22 |
| Amlodipine Besylate | 47 | $312 | $7 |
| Warfarin | 11 | $308 | $28 |
| Low-Ogestrel | 16 | $291 | $18 |
| Baclofen | 32 | $276 | $9 |
| Sertraline | 12 | $222 | $18 |
| Glipizide | 25 | $216 | $9 |
| Lisinopril-Hydrochlorothiazide | 16 | $197 | $12 |
| Metformin | 27 | $196 | $7 |
| Pravastatin | 11 | $174 | $16 |
| Topiramate | 14 | $171 | $12 |
| Hydrocodone-Acetaminophen | 11 | $159 | $14 |
| Triamcinolone Acetonide | 16 | $140 | $9 |
| Nitrofurantoin Mono-Macro | 11 | $134 | $12 |
| Metoprolol | 20 | $131 | $7 |
| Trazodone | 15 | $130 | $9 |
| Hydrochlorothiazide | 23 | $101 | $4 |
| Ibuprofen | 11 | $90 | $8 |
| Zolpidem | 13 | $89 | $7 |
| Acyclovir | 11 | $77 | $7 |
| Citalopram Hbr | 17 | $69 | $4 |
| Simvastatin | 11 | $68 | $6 |
2019: 11 drugs
| Proair Hfa | 27 | $2,615 | $97 |
| Gabapentin | 21 | $1,212 | $58 |
| Levothyroxine | 32 | $673 | $21 |
| Atorvastatin | 39 | $542 | $14 |
| Potassium Chloride | 15 | $499 | $33 |
| Omeprazole | 36 | $430 | $12 |
| Metformin | 19 | $134 | $7 |
| Trazodone | 14 | $122 | $9 |
| Lisinopril | 18 | $116 | $6 |
| Amlodipine Besylate | 16 | $90 | $6 |
| Hydrochlorothiazide | 13 | $81 | $6 |
2018: 11 drugs
| Proair Hfa | 13 | $868 | $67 |
| Atorvastatin | 25 | $668 | $27 |
| Duloxetine | 18 | $659 | $37 |
| Levothyroxine | 25 | $529 | $21 |
| Omeprazole | 29 | $399 | $14 |
| Lisinopril | 35 | $265 | $8 |
| Metformin | 14 | $124 | $9 |
| Metoprolol | 14 | $96 | $7 |
| Simvastatin | 17 | $84 | $5 |
| Hydrochlorothiazide | 18 | $65 | $4 |
| Amlodipine Besylate | 12 | $44 | $4 |
2017: 5 drugs
| Levothyroxine | 17 | $282 | $17 |
| Oxycodone | 13 | $199 | $15 |
| Tri-Lo-Sprintec | 15 | $164 | $11 |
| Ciprofloxacin | 12 | $156 | $13 |
| Hydrocodone-Acetaminophen | 13 | $80 | $6 |
Money from drug and device companies
$571 in 2025
| 2025 | 15 | 21 | None | $571 |
| 2024 | 2 | 3 | None | $68 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Hologic Sales and Service | Trident Specimen Radiography System | $105 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $100 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $70 | 3 payments
|
| Legend Biotech USA | Carvykti | $43 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $29 | 1 payment
|
| Lilly USA | Cyramza | $27 | 1 payment
|
See all 21 published payments
| Puma Biotechnology | Meals · 2025-11-11 | Nerlynx | $22 |
| Abbvie | Meals · 2025-10-30 | Elahere | $26 |
| Daiichi Sankyo | Meals · 2025-10-23 | Enhertu | $19 |
| Incyte | Meals · 2025-10-01 | Zynyz | $26 |
| Agios Pharmaceuticals | Meals · 2025-09-18 | Pyrukynd | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-05 | Enhertu | $34 |
| Lilly USA | Meals · 2025-08-25 | Cyramza | $27 |
| Merck Sharp & Dohme | Meals · 2025-08-05 | Keytruda | $28 |
| Legend Biotech USA | Meals · 2025-07-14 | Carvykti | $16 |
| Legend Biotech USA | Meals · 2025-07-14 | Carvykti | $28 |
| Pharmacosmos Therapeutics | Meals · 2025-06-27 | Monoferric | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-28 | Enhertu | $18 |
| Merck Sharp & Dohme | Meals · 2025-05-20 | Keytruda | $25 |
| Hologic Sales and Service | Meals · 2025-05-02 | Trident Specimen Radiography System | $105 |
| Eisai | Meals · 2025-04-28 | Lenvima | $21 |
| Janssen Biotech | Meals · 2025-03-25 | Darzalex | $21 |
| Rigel Pharmaceuticals | Meals · 2025-02-06 | Tavalisse | $29 |
| Merck Sharp & Dohme | Meals · 2025-01-28 | Keytruda | $23 |
| Myriad Genetic Laboratories | Meals · 2025-01-27 | Myrisk | $24 |
| Merck Sharp & Dohme | Meals · 2025-01-16 | Keytruda | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-15 | Lynparza | $18 |
See earlier years (2024)
2024: $68
| Abbvie | Imbruvica | $45 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $22 | 1 payment
|
Professional record
- NPI
- 1760861827
- Licence
- CA PA61319, OR PA179814
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, surgical (363AS0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-05-22
- NPI last updated
- 2025-12-23
- NPI record certified
- 2025-12-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4920 N Interstate Ave, Portland, OR, 97217
This office lists an electronic records connection.